|
|
||||||||
1 From the Department of Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas; and the 2 Department of Immunology, St. Paul Medical Center, Mary Kay Ash Institute for Cancer Research, Dallas, Texas.
PURPOSE. To determine the cholinergic (carbachol, CCH) and adrenergic (norepinephrine, NE) modulation of Ca2+ response to endothelin-1 in human ciliary smooth muscle (HCSM) cells.
METHODS. Intracellular calcium levels were measured using the Fura-2 calcium imaging system in HCSM cells treated either singly with endothelin-1 (ET-1; 2200 nM), CCH (1100 µM), NE (0.110 µM) or isoproterenol (ISO; 1 µM) or in combinations of CCH, NE, or ISO with ET-1. Intracellular cAMP levels after NE and ISO treatments were also measured using a radioimmunoassay.
RESULTS. Endothelin-1 dose-dependently increased [Ca2+]i and was characteristically biphasic (peak [Ca2+]i for ET-1: 2 nM, 517 ± 73 nM; 20 nM, 785 ± 65 nM; and 200 nM, 2564 ± 359 nM). Carbachol also dose-dependently increased [Ca2+]i; however, subsequent additions of ET-1 (200 nM) resulted in lower [Ca2+]i (100 µM CCH + ET-1; 300 ± 21 nM) compared with that observed with 200 nM ET-1 alone (2564 ± 359 nM). Norepinephrine pretreatment also decreased ET-1induced [Ca2+]i (10 µM NE + ET-1; 619 ± 64 nM) compared with ET-1 alone, and NEs effect could be reversed by propranolol (ß-adrenergic antagonist) treatment. Neither CCH nor NE was able to completely abolish ET-1s ability to mobilize calcium in HCSM cells. Isoproterenol (a ß-agonist) mimicked NEs effect on ET-1induced [Ca2+]i (1 µM ISO + ET-1; 254 ± 56 nM). Both ISO and NE elevated [cAMP] in HCSM cells.
CONCLUSIONS. In HCSM cells, CCH and ET-1 can activate common as well as specific [Ca2+]i pools. The reduction in ET-1induced [Ca2+]i after NE/ISO treatment appears to be due to elevated cAMP levels via ß-receptor activation, suggesting the existence of receptor cross talk. The ability of CCH and NE to modulate ET-1s actions on HCSM may be relevant to the regulation of ciliary muscle contraction and aqueous humor outflow.
This article has been cited by other articles:
![]() |
K. T. Tchedre, R.-Q. Huang, A. Dibas, R. R. Krishnamoorthy, G. H. Dillon, and T. Yorio Sigma-1 Receptor Regulation of Voltage-Gated Calcium Channels Involves a Direct Interaction Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4993 - 5002. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. T. Tchedre and T. Yorio {sigma}-1 Receptors Protect RGC-5 Cells from Apoptosis by Regulating Intracellular Calcium, Bax Levels, and Caspase-3 Activation Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2577 - 2588. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. He, A. Dibas, T. Yorio, and G. Prasanna Parallel Signaling Pathways in Endothelin-1-Induced Proliferation of U373MG Astrocytoma Cells Exp Biol Med, March 1, 2007; 232(3): 370 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. O. Mathew, P. R. Kumaresan, J. K. Lee, V. T. Huynh, and P. A. Mathew Mutational Analysis of the Human 2B4 (CD244)/CD48 Interaction: Lys68 and Glu70 in the V Domain of 2B4 Are Critical for CD48 Binding and Functional Activation of NK Cells J. Immunol., July 15, 2005; 175(2): 1005 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhang, A. F. Clark, and T. Yorio Interactions of Endothelin-1 with Dexamethasone in Primary Cultured Human Trabecular Meshwork Cells Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5301 - 5308. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Narayan, G. Prasanna, R. R. Krishnamoorthy, X. Zhang, and T. Yorio Endothelin-1 Synthesis and Secretion in Human Retinal Pigment Epithelial Cells (ARPE-19): Differential Regulation by Cholinergics and TNF-{alpha} Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4885 - 4894. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Prasanna, R. Krishnamoorthy, A. F. Clark, R. J. Wordinger, and T. Yorio Human Optic Nerve Head Astrocytes as a Target for Endothelin-1 Invest. Ophthalmol. Vis. Sci., August 1, 2002; 43(8): 2704 - 2713. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |